Skip to content
MMJ Gazette
  Tuesday 13 January 2026
  • About
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
  • Authors
  • Home
  • News
  • CBD
  • Cannabis
  • Drugs
  • Marijuana
  • Tobacco
  • Law
Trending
January 10, 2026Cannabis Firms Face HR Compliance Crunch in 2026 January 9, 2026Oregon Cannabis Sales Drop in 2025 Despite Record Harvests January 8, 2026Kentucky’s Medical Weed Market Faces Major Supply Hurdles January 7, 2026Vireo Growth Buys Eaze in $47M Cannabis Shakeup January 5, 2026Chanda Macias Drives Global Medical Cannabis Access January 3, 2026Trump’s Marijuana Shift: Answers to Your Burning Questions on Tax Relief January 2, 2026Marijuana Rescheduling Sparks Tax Relief Hopes – But When? January 1, 2026Three Trends Reshaping U.S. Cannabis in 2026 December 30, 2025Trump’s Cannabis Shift Sparks Hope for Parkinson’s Relief December 24, 2025Anti-Weed Group Funds Bid to Kill Pot Sales in Maine, Mass
MMJ Gazette
MMJ Gazette
  • About
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
  • Authors
MMJ Gazette
  Cannabis  Trump Eyes Major Shift in Cannabis Rules
CannabisNews

Trump Eyes Major Shift in Cannabis Rules

Lars BeckersLars Beckers—December 16, 20250
FacebookTwitterPinterestLinkedInTumblrRedditVKWhatsAppEmail

President Donald Trump just dropped a bombshell that could shake up America’s weed industry big time. On Monday, he said the White House is seriously looking at easing federal rules on marijuana, a change that might supercharge the $32 billion legal market. But hold on, he gave no clear timeline, shooting down last week’s buzz about a quick executive order to bump it to Schedule 3. What’s next for pot policy under Trump?

Trump’s words came out strong during a recent chat, confirming the administration is “very strongly” thinking about relaxing cannabis restrictions. This isn’t just talk; it points to a possible reclassification from Schedule 1, where it’s lumped with heavy hitters like heroin, to Schedule 3, alongside milder drugs like some painkillers.

This move could slash taxes for cannabis businesses and open doors to banking services they’ve long been shut out from. Right now, federal law treats marijuana as super dangerous with no medical value, blocking companies from normal financial tools.

Industry folks are buzzing with hope. For years, they’ve fought IRS rules that hit them with huge tax bills because they can’t deduct basic expenses. A Schedule 3 shift would fix that, letting firms keep more cash and grow faster.

But Trump played it cool on timing. He didn’t promise anything soon, which means that hot tip from last week about an order dropping Monday? It’s already a bust. Sources close to the matter say talks are ongoing, but no one’s rushing.

The Push for Change and Industry Impact

Cannabis leaders have been lobbying hard. At a big fundraiser earlier this year, execs from top companies pitched Trump directly on finishing what started under Biden but never got done. They want marijuana recognized for its medical perks, which could mean easier research and wider access.

Picture this: if reclassified, pot could get prescribed more like regular meds, maybe even covered by insurance in some cases. That’s huge for patients dealing with pain, anxiety, or other issues where cannabis helps.

Stocks tell the story of excitement. When rumors flew about an imminent order, shares in weed companies jumped. Investors see dollar signs in less red tape and more mainstream appeal.

Still, not everyone’s cheering without caution. Some worry about new federal oversight that might come with the change, like stricter rules on sales or testing.

  • Tax relief: No more killer deductions ban under IRS code 280E.
  • Banking boost: Firms could finally use credit cards and loans without fear.
  • Medical wins: Easier paths for studies and prescriptions.

One short take: This isn’t full legalization, but it’s a step that could pave the way.

Background on Federal Weed Laws

Marijuana’s been stuck in Schedule 1 since the 1970s, a spot reserved for drugs seen as highly addictive with zero benefits. That clashes with reality today, where most states have legalized it for medical or recreational use.

Trump’s not the first to eye a fix. The previous administration kicked off a review, but it stalled. Now, with Trump back in charge, pressure’s mounting from voters and businesses alike. Polls show over 70% of Americans support some form of legalization, up from decades ago.

Why Schedule 3? It admits the drug has accepted medical uses and lower abuse risk. Think ketamine or certain steroids – regulated but not banned outright.

This fits Trump’s past nods to reform. During his first term, he signed a farm bill that legalized hemp, a cannabis cousin. Supporters say he’s pragmatic, seeing economic upside in a booming industry.

Challenges and What’s Ahead

Not everything’s smooth sailing. Critics argue an executive order might face legal pushback, since rescheduling usually goes through a formal process with the DEA and public input.

Industry watchers point out potential downsides too. Stricter FDA involvement could mean big pharma muscling in, squeezing out smaller players.

Plus, states with legal weed already deal with a patchwork of rules. Federal change wouldn’t erase those, but it could harmonize things and cut conflicts.

Looking forward, this could spark bigger moves, like full decriminalization. But Trump stressed any shift would come with “smart regulations” to keep things safe.

Experts say watch for signals from key advisors. If momentum builds, we might see action by early next year.

In a recent survey by Gallup in 2024, support for marijuana legalization hit a record high, showing public opinion’s shift.

Trump’s hint at cannabis reform isn’t just policy wonk stuff; it could reshape how millions access and use weed, boost jobs in a growing field, and even influence elections where pot’s a hot button. As details emerge, the industry holds its breath for real change that matches state progress with federal nods.

FacebookTwitterPinterestLinkedInTumblrRedditVKWhatsAppEmail

Lars Beckers

Lars Beckers is a distinguished senior content writer at MMJ Gazette, bringing a wealth of experience and expertise to the realm of medical marijuana and cannabis-related content. With a deep understanding of the industry and a passion for sharing knowledge, Lars's articles offer readers comprehensive insights and engaging narratives in the dynamic world of cannabis. Known for his meticulous research, clarity of expression, and commitment to delivering high-quality content, Lars brings a seasoned perspective to his work, educating and informing audiences on the latest trends and developments in the field.

New York Cannabis Boss Quits Amid Massive Probe Failure
Connecticut Cannabis Prices Keep Falling in November
Related posts
  • Related posts
  • More from author
Cannabis

Cannabis Firms Face HR Compliance Crunch in 2026

January 10, 20260
Cannabis

Oregon Cannabis Sales Drop in 2025 Despite Record Harvests

January 9, 20260
Marijuana

Kentucky’s Medical Weed Market Faces Major Supply Hurdles

January 8, 20260
Load more
Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

SEARCH
PROMOTIONS
RECENT POSTS
  • Cannabis Firms Face HR Compliance Crunch in 2026
  • Oregon Cannabis Sales Drop in 2025 Despite Record Harvests
  • Kentucky’s Medical Weed Market Faces Major Supply Hurdles
  • Vireo Growth Buys Eaze in $47M Cannabis Shakeup
  • Chanda Macias Drives Global Medical Cannabis Access
  • Trump’s Marijuana Shift: Answers to Your Burning Questions on Tax Relief
  • Marijuana Rescheduling Sparks Tax Relief Hopes – But When?
  • Three Trends Reshaping U.S. Cannabis in 2026
  • Trump’s Cannabis Shift Sparks Hope for Parkinson’s Relief
  • Anti-Weed Group Funds Bid to Kill Pot Sales in Maine, Mass
    © MMJ Gazette. 2024
    • About
    • Contact Us
    • Privacy Policy
    • Terms and Conditions
    • Authors